about
Conjugation of Methotrexate-Amino Derivatives to Macromolecules through Carboxylate Moieties Is Superior Over Conventional Linkage to Amino Residues: Chemical, Cell-Free and In Vitro CharacterizationsRecent trends in targeted anticancer prodrug and conjugate design.Human carboxymethylenebutenolidase as a bioactivating hydrolase of olmesartan medoxomil in liver and intestine.Absorption enhancement of adefovir dipivoxil by incorporating MCT and ethyl oleate complex oil phase in emulsion.Computer-aided identification of Trypanosoma brucei uridine diphosphate galactose 4'-epimerase inhibitors: toward the development of novel therapies for African sleeping sickness.Treating attention-deficit/hyperactivity disorder in adults: focus on once-daily medications.Strategies to improve oral drug bioavailability.Riluzole prodrugs for melanoma and ALS: design, synthesis, and in vitro metabolic profiling.Cyclization-activated prodrugs.A novel prodrug strategy to improve the oral absorption of O-desmethylvenlafaxine.Design, Synthesis, and Biological Evaluation of Potential Prodrugs Related to the Experimental Anticancer Agent Indotecan (LMP400).Self-assembled nucleolipids: from supramolecular structure to soft nucleic acid and drug delivery devices.Paclitaxel drug delivery systems.Nanoformulation and encapsulation approaches for poorly water-soluble drug nanoparticles.Advances in oral delivery of anti-cancer prodrugs.Targeting ketone drugs towards transport by the intestinal peptide transporter, PepT1.Comparative pharmacokinetics and bile transformation of R-enantiomer and racemic bambuterol after single-dose intravenous, oral administration in rats and beagle dogs.Preclinical development of drug delivery systems for paclitaxel-based cancer chemotherapy.LC-MS/MS and chiroptical spectroscopic analyses of multidimensional metabolic systems of chiral thalidomide and its derivatives.Macromolecular prodrugs of aspirin with HPMC: A nano particulate drug design, characterization, and pharmacokinetic studies
P2860
Q28552570-544EDD93-AC01-4301-AE8B-D5FB844F6799Q33573762-2C8E84A8-DDFC-45EB-A5C1-9D97E9F90BE3Q33782444-D9C3FEAB-CE14-4F73-88F6-D6A1B96F4859Q33858985-4D8830D3-638A-4437-950C-076A8B00E38BQ33954211-426042ED-CD84-4157-8BFB-E1DE777EDD90Q35833310-0D72ADAF-1713-4F97-9E1D-04B831DE75D1Q36316751-68593641-4BCA-42D5-8957-D53C3FEC3731Q36390918-B177B7D0-EDC3-4EE2-BE5C-5B781F4CFDD3Q37027131-AFA5B4B2-A7FD-4580-B519-9215079EBA6EQ37204088-977F4027-2D88-4DD5-BE30-EF9DEEB3DDB4Q37652515-F0D3C8F8-FADA-416C-AD7F-2C91D10E163CQ37954999-464A5C77-B673-4DC0-805D-6B532D74178BQ38071668-6F2015FC-F5C3-41BE-8453-7FE999EE5EB8Q38687039-B6ADECCF-AD94-4A53-BB5C-929A0CADAE3DQ38862820-7FE46A7E-0B6F-499B-BF36-AE6B8496E1D9Q41904028-7A217048-1809-49A4-BBD1-41B526353FE8Q46830391-107D4CC3-F6E2-427D-840A-B3DA711706FCQ47621457-EF6544D2-90F9-4742-97AE-AD5473F6BAA7Q48259058-2D61E77F-0448-4D6F-804B-3B407843A84BQ57353316-CBFE369E-88B1-458D-BFA4-3F01206194B2
P2860
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh-hant
name
Prodrug research: futile or fertile?
@en
Prodrug research: futile or fertile?
@nl
type
label
Prodrug research: futile or fertile?
@en
Prodrug research: futile or fertile?
@nl
prefLabel
Prodrug research: futile or fertile?
@en
Prodrug research: futile or fertile?
@nl
P1476
Prodrug research: futile or fertile?
@en
P2093
Bernard Testa
P304
P356
10.1016/J.BCP.2004.07.005
P407
P577
2004-12-01T00:00:00Z